固定剂量复方制剂的复兴：佳息患。
The renaissance of fixed dose combinations: Combivir.
出版信息
Ther Clin Risk Manag. 2007 Aug;3(4):579-83.
Abstract
Combivir is a fixed dose combination tablet of two antiretroviral drugs; zidovudine and lamivudine, used in the treatment of HIV-1 infection. AZT was the first antiretroviral used in clinical trials and the addition of lamivudine improved its effectiveness. With the introduction of highly active antiretroviral therapy in the form of a combination of three drugs including two nucleoside analogues, Combivir became the gold standard nucleoside 'backbone' until very recently. Combivir was the first combination agent and simplified HIV therapy greatly. The introduction of newer fixed dose combinations with the advantage of once daily dosing and improved tolerability and toxicity profiles has made Combivir a less popular choice in treatment naïve individuals needing to start therapy.
摘要
克立芝是一种固定剂量的复方片剂，含有两种抗逆转录病毒药物：齐多夫定和拉米夫定，用于治疗 HIV-1 感染。AZT 是第一种在临床试验中使用的抗逆转录病毒药物，而拉米夫定的加入提高了它的疗效。随着高效抗逆转录病毒疗法以三种药物（包括两种核苷类似物）联合应用的形式出现，克立芝成为了非常近之前的核苷“骨干”金标准。克立芝是第一种联合药物，极大地简化了 HIV 治疗。具有每日一次给药的优势以及改善的耐受性和毒性特征的新型固定剂量组合的出现，使得克立芝在需要开始治疗的初治个体中，不再是一个受欢迎的选择。
相似文献
1
The renaissance of fixed dose combinations: Combivir.固定剂量复方制剂的复兴：佳息患。
Ther Clin Risk Manag. 2007 Aug;3(4):579-83.
2
3
Twice-daily Trizivir versus Combivir-abacavir in antiretroviral-experienced adults with human immunodeficiency virus-1 infection: a formulation-switch trial.对于有人类免疫缺陷病毒1型感染且有抗逆转录病毒治疗经验的成人患者，每日两次服用三协唯与服用双汰芝-阿巴卡韦的对比：一项剂型转换试验。
Pharmacotherapy. 2003 Nov;23(11):1432-40. doi: 10.1592/phco.23.14.1432.31944.
4
5
Toxicology and Carcinogenesis Studies of Mixtures of 3'-Azido-3'-Deoxythymidine (AZT), Lamivudine (3TC), and Nevirapine (NVP) (CAS Nos. 30516-87-1, 134678-17-4, 129618-40-2) in Genetically Modified C3B6.129F1-Trp53(tm1Brd) N12 Haploinsufficient Mice (in utero and postnatal gavage studies).3'-叠氮-3'-脱氧胸苷（AZT）、拉米夫定（3TC）和奈韦拉平（NVP）（化学物质登记号分别为30516-87-1、134678-17-4、129618-40-2）混合物对转基因C3B6.129F1-Trp53(tm1Brd) N12单倍体不足小鼠的毒理学和致癌性研究（宫内和出生后灌胃研究）
Natl Toxicol Program Genet Modif Model Rep. 2013 Oct(16):1-236.
6
Genotoxic and Cytotoxic Effects of Antiretroviral Combinations in Mice Bone Marrow.抗逆转录病毒药物组合对小鼠骨髓的遗传毒性和细胞毒性作用。
PLoS One. 2016 Nov 2;11(11):e0165706. doi: 10.1371/journal.pone.0165706. eCollection 2016.
7
A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity.一项针对初治抗逆转录病毒治疗患者的前瞻性96周研究，评估三协唯、双汰芝/奈非那韦以及拉米夫定/司他夫定/奈非那韦对脂质、代谢参数及疗效的影响：性别和种族的作用
HIV Med. 2006 Mar;7(2):85-98. doi: 10.1111/j.1468-1293.2006.00346.x.
8
Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.替诺福韦或齐多夫定与一种核苷类逆转录酶抑制剂及一种非核苷类逆转录酶抑制剂联合用于初治抗逆转录病毒治疗的人类免疫缺陷病毒感染个体的初始治疗。
Cochrane Database Syst Rev. 2010 Oct 6(10):CD008740. doi: 10.1002/14651858.CD008740.
9
Emtricitabine/tenofovir disoproxil fumarate.恩曲他滨/替诺福韦酯富马酸盐
Drugs R D. 2004;5(3):160-1. doi: 10.2165/00126839-200405030-00004.
10
What you need to know about Combivir.关于双汰芝你需要了解的内容。
AIDS Alert. 1998 Jan;13(1):suppl 1.
引用本文的文献
1
Peptide hydrogel-drug conjugates for tailored disease treatment.用于定制疾病治疗的肽水凝胶-药物偶联物。
Mater Today Bio. 2024 Dec 25;31:101423. doi: 10.1016/j.mtbio.2024.101423. eCollection 2025 Apr.
2
A Review of FDA-Approved Anti-HIV-1 Drugs, Anti-Gag Compounds, and Potential Strategies for HIV-1 Eradication.抗 HIV-1 药物、抗 gag 化合物的 FDA 批准进展及 HIV-1 清除的潜在策略综述
Int J Mol Sci. 2024 Mar 25;25(7):3659. doi: 10.3390/ijms25073659.
3
Promising Schiff bases in antiviral drug design and discovery.抗病毒药物设计与发现中前景广阔的席夫碱
Med Chem Res. 2023;32(6):1063-1076. doi: 10.1007/s00044-023-03068-0. Epub 2023 May 10.
4
Fetal cardiac evaluation in HIV-positive women under HAART therapy in a Romanian hospital.罗马尼亚一家医院对接受高效抗逆转录病毒治疗的艾滋病毒阳性女性进行胎儿心脏评估。
Exp Ther Med. 2021 Jun;21(6):606. doi: 10.3892/etm.2021.10038. Epub 2021 Apr 14.
5
Cyanovirin-N produced in rice endosperm offers effective pre-exposure prophylaxis against HIV-1BaL infection in vitro.在水稻胚乳中产生的氰苷蛋白 - N 在体外对 HIV - 1BaL 感染提供有效的暴露前预防。
Plant Cell Rep. 2016 Jun;35(6):1309-19. doi: 10.1007/s00299-016-1963-5. Epub 2016 Mar 23.
6
Prophylactic and therapeutic effect of AZT/3TC in RT-SHIV infected Chinese-origin rhesus macaques.AZT/3TC 在感染 RT-SHIV 的中国来源恒河猴中的预防和治疗效果。
AIDS Res Ther. 2014 Mar 4;11(1):12. doi: 10.1186/1742-6405-11-12.
7
Changes in first-line cART regimens and short-term clinical outcome between 1996 and 2010 in The Netherlands.1996 年至 2010 年期间荷兰一线抗逆转录病毒治疗方案的变化与短期临床结局。
PLoS One. 2013 Sep 30;8(9):e76071. doi: 10.1371/journal.pone.0076071. eCollection 2013.
8
Microbicides in the prevention of HIV infection: current status and future directions.HIV 感染预防中的杀微生物剂：现状与未来方向。
Drugs. 2010 Jul 9;70(10):1231-43. doi: 10.2165/10898650-000000000-00000.
本文引用的文献
1
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.初治抗逆转录病毒治疗患者中，替诺福韦酯富马酸盐、恩曲他滨和依非韦伦与固定剂量齐多夫定/拉米夫定和依非韦伦的比较：病毒学、免疫学和形态学变化——一项96周分析
J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):535-40. doi: 10.1097/01.qai.0000245886.51262.67.
2
The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations.人类免疫缺陷病毒1型逆转录酶中的K65R突变与胸苷类似物突变表现出双向表型拮抗作用。
J Virol. 2006 May;80(10):4971-7. doi: 10.1128/JVI.80.10.4971-4977.2006.
3
Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study).拉米夫定单药治疗对携带拉米夫定耐药病毒的HIV-1感染患者的疗效：一项随机试点研究（E-184V研究）
AIDS. 2006 Apr 4;20(6):795-803. doi: 10.1097/01.aids.0000218542.08845.b2.
4
The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations.人类免疫缺陷病毒1型逆转录酶中的L74V突变可抵消与胸苷类似物耐药性突变相关的齐多夫定单磷酸增强切除作用。
Antimicrob Agents Chemother. 2005 Jul;49(7):2648-56. doi: 10.1128/AAC.49.7.2648-2656.2005.
5
Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules.从每日两次转换为每日一次的抗逆转录病毒疗法治疗HIV时维持更好的依从性：一项使用司他夫定缓释胶囊进行治疗简化的24周随机试验。
HIV Med. 2005 May;6(3):185-90. doi: 10.1111/j.1468-1293.2005.00287.x.
6
Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment.与核苷类逆转录酶抑制剂治疗相比，富马酸替诺福韦二吡呋酯治疗相关的肾功能变化。
Clin Infect Dis. 2005 Apr 15;40(8):1194-8. doi: 10.1086/428840. Epub 2005 Mar 17.
7
Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults.阿巴卡韦与齐多夫定联合拉米夫定和依非韦伦治疗初治的成人HIV感染者的比较。
Clin Infect Dis. 2004 Oct 1;39(7):1038-46. doi: 10.1086/424009. Epub 2004 Sep 10.
8
Assessing teratogenicity of antiretroviral drugs: monitoring and analysis plan of the Antiretroviral Pregnancy Registry.评估抗逆转录病毒药物的致畸性：抗逆转录病毒妊娠登记处的监测与分析计划
Pharmacoepidemiol Drug Saf. 2004 Aug;13(8):537-45. doi: 10.1002/pds.982.
9
Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.三联核苷类方案与含依非韦伦方案用于初治HIV-1感染
N Engl J Med. 2004 Apr 29;350(18):1850-61. doi: 10.1056/NEJMoa031772.
10
Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study.从胸腺嘧啶核苷类似物转换为阿巴卡韦2年后HIV感染患者脂肪萎缩的可逆性：MITOX扩展研究
AIDS. 2004 Apr 30;18(7):1029-36. doi: 10.1097/00002030-200404300-00011.
Zotero 插件